PL2303267T3 - Polimorficzna postać pochodnej [1,2,4]triazolo[4,3-a]pirydyny do leczenia chorób zapalnych - Google Patents

Polimorficzna postać pochodnej [1,2,4]triazolo[4,3-a]pirydyny do leczenia chorób zapalnych

Info

Publication number
PL2303267T3
PL2303267T3 PL09708402T PL09708402T PL2303267T3 PL 2303267 T3 PL2303267 T3 PL 2303267T3 PL 09708402 T PL09708402 T PL 09708402T PL 09708402 T PL09708402 T PL 09708402T PL 2303267 T3 PL2303267 T3 PL 2303267T3
Authority
PL
Poland
Prior art keywords
triazolo
inflammatory diseases
polymorphic form
treating inflammatory
pyridine derivative
Prior art date
Application number
PL09708402T
Other languages
English (en)
Inventor
Kenneth John Butcher
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PL2303267T3 publication Critical patent/PL2303267T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
PL09708402T 2008-02-04 2009-01-28 Polimorficzna postać pochodnej [1,2,4]triazolo[4,3-a]pirydyny do leczenia chorób zapalnych PL2303267T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2587908P 2008-02-04 2008-02-04
EP09708402.4A EP2303267B1 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a]pyridine derivative for treating inflammatory diseases
PCT/IB2009/050351 WO2009098612A2 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases

Publications (1)

Publication Number Publication Date
PL2303267T3 true PL2303267T3 (pl) 2013-11-29

Family

ID=40911989

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09708402T PL2303267T3 (pl) 2008-02-04 2009-01-28 Polimorficzna postać pochodnej [1,2,4]triazolo[4,3-a]pirydyny do leczenia chorób zapalnych

Country Status (22)

Country Link
US (1) US8222273B2 (pl)
EP (1) EP2303267B1 (pl)
JP (1) JP5344942B2 (pl)
KR (2) KR101422318B1 (pl)
CN (1) CN101939320B (pl)
AR (1) AR070411A1 (pl)
AU (1) AU2009211072B2 (pl)
BR (1) BRPI0907463A2 (pl)
CA (1) CA2712574C (pl)
CY (1) CY1114389T1 (pl)
DK (1) DK2303267T3 (pl)
ES (1) ES2423991T3 (pl)
IL (1) IL206948A (pl)
MX (1) MX2010008535A (pl)
NZ (1) NZ587094A (pl)
PL (1) PL2303267T3 (pl)
PT (1) PT2303267E (pl)
RU (1) RU2448966C1 (pl)
SI (1) SI2303267T1 (pl)
TW (1) TWI391391B (pl)
WO (1) WO2009098612A2 (pl)
ZA (1) ZA201005137B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
CN105646484A (zh) * 2016-03-01 2016-06-08 孙霖 晶型b及制备方法
CN105693716A (zh) * 2016-03-01 2016-06-22 孙霖 晶型a及制备方法
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
GB201721793D0 (en) 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990182A2 (en) 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
JP3784001B2 (ja) 1998-11-20 2006-06-07 三菱化学株式会社 ５−［｛６−（２−フルオロベンジル）オキシ−２−ナフチル｝メチル］−２，４−チアゾリジンジオンの結晶体
CN1878741A (zh) * 2004-07-16 2006-12-13 Usv有限公司 阿扎伐醌的新颖多晶形物及其制备方法
PL1778686T3 (pl) * 2004-08-12 2009-04-30 Pfizer Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds

Also Published As

Publication number Publication date
IL206948A (en) 2014-12-31
CY1114389T1 (el) 2016-08-31
HK1147481A1 (zh) 2011-08-12
PT2303267E (pt) 2013-08-05
RU2010132639A (ru) 2012-02-10
EP2303267A2 (en) 2011-04-06
ZA201005137B (en) 2011-03-30
DK2303267T3 (da) 2013-09-02
US20110003848A1 (en) 2011-01-06
ES2423991T3 (es) 2013-09-26
EP2303267B1 (en) 2013-07-03
US8222273B2 (en) 2012-07-17
JP2009185028A (ja) 2009-08-20
BRPI0907463A2 (pt) 2019-09-24
AU2009211072A1 (en) 2009-08-13
NZ587094A (en) 2011-07-29
AU2009211072B2 (en) 2014-01-23
WO2009098612A3 (en) 2009-10-08
RU2448966C1 (ru) 2012-04-27
CN101939320B (zh) 2013-11-20
IL206948A0 (en) 2010-12-30
CA2712574A1 (en) 2009-08-13
CN101939320A (zh) 2011-01-05
KR101422318B1 (ko) 2014-07-22
TW200944524A (en) 2009-11-01
CA2712574C (en) 2014-01-07
SI2303267T1 (sl) 2013-09-30
TWI391391B (zh) 2013-04-01
WO2009098612A2 (en) 2009-08-13
KR20100108409A (ko) 2010-10-06
MX2010008535A (es) 2010-08-30
AR070411A1 (es) 2010-04-07
KR20130087048A (ko) 2013-08-05
JP5344942B2 (ja) 2013-11-20

Similar Documents

Publication Publication Date Title
PL2303267T3 (pl) Polimorficzna postać pochodnej [1,2,4]triazolo[4,3-a]pirydyny do leczenia chorób zapalnych
IL204720A0 (en) Imidazo [1, 2 - a] pyridine derivatives useful as alk inhibitors
IL211128A0 (en) Method for producing amide derivative
ZA201105896B (en) [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
PT2124944E (pt) Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
BRPI0915417A2 (pt) derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina como inibidores da met quinase
SI2121553T1 (sl) Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov
IL183447A0 (en) Substituted pteridines for treating inflammatory diseases
ZA201008841B (en) 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases
IL210610A0 (en) Process for producing 6-aryloxyquinoline derivative and intermediate thereof
IL186904A0 (en) Novel compounds for treating inflammatory diseases
EP2248810A4 (en) METHOD FOR PRODUCING A PHENOXYPYRIDINE DERIVATIVE
SI2155679T1 (sl) Metoda za pripravo derivatov 4-formilaminopiperidina
IL209999A0 (en) Nifurtimox for treating diseases caused by trichomonadida
MX295359B (en) Improved method for producing nitroguanidine derivative
IL198589A0 (en) Method for producing 2-alkyl-3-aminothiophene derivative
ZA201106360B (en) Method for manufacturing 1,5-benzodiazepine derivative
IL204792A0 (en) Method for producing pyrazolinone derivative
EP1997812A4 (en) PROCESS FOR THE PREPARATION OF A CHINAZOLIN-4-ON DERIVATIVE
ZA200707592B (en) Novel compounds for treating inflammatory diseases
EP2299815A4 (en) METHOD OF TREATING BURNS USING AVERMECTIN COMPOUND
EP2216337A4 (en) METHOD FOR PRODUCING A 4-DESOXY-4-FLUOR-D-GLUCOSE DERIVATIVE
IL206085A0 (en) Process for producing of pyrazolinone derivative
EP2002840A4 (en) METHOD FOR THE TREATMENT OF ONCOLOGICAL ILLNESSES
GB0504337D0 (en) Process for producing 2-benzoyloxy oxyacetaldehyde derivative